Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease

Merck KGaA (EMD Serono)

Status and phase: Terminated; Phase 2

Conditions: Crohn's Disease

Treatments: Drug: Interferon beta-1a

Study type: Interventional

Funder types: Industry

Identifiers

NCT00304252

9903 (Other Identifier)

22916

Details and patient eligibility

About

The purpose of this study is to determine the safety and efficacy of interferon beta-1a in maintaining remission in patients with Crohn's disease.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with an established diagnosis of Crohn's disease who went into remission using corticosteroids within 4 weeks before the study

Exclusion criteria

• Any other treatment for the maintenance of remission of Crohn's disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind